Sage Therapeutics (Nasdaq:SAGE) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

SAGE 주식 개요

세이지 테라퓨틱스는 바이오 제약 회사로 뇌 건강 의약품을 개발 및 상용화하는 기업입니다.

SAGE 기본 분석
눈송이 점수
가치 평가	4/6
미래 성장	2/6
과거 실적	0/6
재무 상태	5/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 90% 에서 거래

수익은 연간 42.85% 증가할 것으로 예상됩니다.

위험 분석

최근 3개월간 주가 변동성

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

Sage Therapeutics, Inc. 경쟁사

AnaptysBio

NasdaqGS:ANAB

US$677.5m

Mereo BioPharma Group

NasdaqCM:MREO

US$530.9m

Relay Therapeutics

NasdaqGM:RLAY

US$836.3m

I-Mab

NasdaqGM:IMAB

US$136.4m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Sage Therapeutics
과거 주가
현재 주가	US$10.86
52주 최고치	US$49.74
52주 최저치	US$9.76
베타	0.92
11개월 변경	0%
3개월 변경 사항	-42.05%
1년 변경 사항	-76.90%
33년 변화	-80.62%
5년 변화	-93.87%
IPO 이후 변화	-63.80%

최근 뉴스 및 업데이트

Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data

May 30

Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?

May 21

Recent updates

Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data

May 30

Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?

May 21

Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%

Feb 22

Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Feb 15

Sizing Up Sage Therapeutics

Jan 22

Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade

Aug 09

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Feb 22

An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued

Nov 12

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Oct 14

Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M

Aug 02

What You Need To Know About The Sage Therapeutics, Inc. (NASDAQ:SAGE) Analyst Downgrade Today

Aug 05

Sage Therapeutics: Showing Upside, But There Are Plenty Of Unknowns

Jul 25

Sage Therapeutics Needs To Show Improved Data To Regain Investor Trust

Jul 12

Sage Therapeutics Q1 2021 Earnings Preview

May 03

주주 수익률

	SAGE	US Biotechs	US 마켓
7D	-2.4%	-0.7%	0.04%
1Y	-76.9%	10.0%	20.7%

수익률 대 산업: SAGE 지난 1년 동안 6.7 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: SAGE 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is SAGE's price volatile compared to industry and market?
SAGE volatility
SAGE Average Weekly Movement	9.9%
Biotechs Industry Average Movement	10.4%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.3%
10% least volatile stocks in US Market	2.8%

안정적인 주가: SAGE 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: SAGE 의 주간 변동성( 10% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2010	487	Barry Greene	www.sagerx.com

세이지 테라퓨틱스는 바이오 제약 회사로 뇌 건강 의약품을 개발 및 상용화하고 있습니다. 세이지의 제품 후보로는 성인 산후 우울증(PPD) 치료를 위한 정맥주사제인 줄레소(ZULRESSO)와 산후 우울증 치료를 위한 시냅스 및 시냅스 외 GABAA 수용체를 모두 표적으로 하는 신경 활성 스테로이드제인 주르주베(ZURZUVAE) 등이 있습니다. 또한 본태성 진전 치료제로 임상 2상 시험 중이며 뇌전증과 파킨슨병에 대한 임상 1상을 완료한 화합물인 SAGE-324와 우울증, 헌팅턴병, 파킨슨병, 알츠하이머병, 주의력결핍 과잉행동장애, 정신분열증, 신경병성 통증 치료를 위해 임상 2상 시험 중인 옥시스테롤 기반 NMDA 수용체의 양성 올스테릭 모듈레이터인 SAGE-718 등 제품 파이프라인을 보유하고 있습니다.

Sage Therapeutics, Inc. 기본 사항 요약

Sage Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
SAGE 기본 통계
시가총액	US$643.35m
수익(TTM)	-US$503.14m
수익(TTM)	US$91.06m

7.2x

P/S 비율

-1.3x

P/E 비율

SAGE 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
SAGE 손익 계산서(TTM)
수익	US$91.06m
수익 비용	US$338.34m
총 이익	-US$247.28m
기타 비용	US$255.87m
수익	-US$503.14m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-8.36
총 마진	-271.55%
순이익 마진	-552.52%
부채/자본 비율	0%

SAGE 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

SAGE 주식 개요

보상

위험 분석

Sage Therapeutics, Inc. 경쟁사

NasdaqGS:ANAB

US$677.5m

NasdaqCM:MREO

US$530.9m

NasdaqGM:RLAY

US$836.3m

NasdaqGM:IMAB

US$136.4m

가격 내역 및 성능

최근 뉴스 및 업데이트

Sage Therapeutics, Inc. Announces Topline Results from the Phase 2 SURVEYOR Study

Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data

Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?

Consensus revenue estimates increase by 32%, EPS downgraded

Sage Therapeutics, Inc., Annual General Meeting, Jun 10, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Sage Therapeutics, Inc. Announces Topline Results from the Phase 2 SURVEYOR Study

Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data

Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?

Consensus revenue estimates increase by 32%, EPS downgraded

Sage Therapeutics, Inc., Annual General Meeting, Jun 10, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 13% to US$24.39

Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease

Sage Therapeutics, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%

Consensus revenue estimates fall by 50%

Consensus revenue estimates fall by 50%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Sage Therapeutics, Inc. to Report Q4, 2023 Results on Feb 14, 2024

Sizing Up Sage Therapeutics

Price target decreased by 13% to US$21.94

Sage Therapeutics, Inc. Announces Changes to Board of Directors

Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIV

Insufficient new directors

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Sage Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Sage Therapeutics, Inc. Announces U.S. Food and Drug Administration Granted Sage-718 Orphan Drug Designation for the Treatment of Huntington's Disease

Sage Therapeutics, Inc. Announces Reduction of the Workforce by Approximately 40%

Consensus revenue estimates fall by 57%

Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 21% to US$48.06

Sage Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Insider recently bought US$51k worth of stock

Consensus revenue estimates increase by 14%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Biogen Inc. and Sage Therapeutics, Inc. Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Sage Therapeutics, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

President recently bought US$500k worth of stock

An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Sage Therapeutics, Inc. Announces Resignation of Jeffrey M. Jonas as Chief Innovation Officer

Sage Therapeutics Appoints Laura M. Gault as Chief Medical Officer

Sage Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Sage Therapeutics and Biogen Present Further Analyses from Phase 3 Skylark Study of Zuranolone in Postpartum Depression At the European College of Neuropsychopharmacology (Ecnp) Congress

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M

Sage Therapeutics, Inc. Enters into Settlement Agreement

Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 1000 Dynamic Index

We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

Sage Therapeutics, Inc. Provides Zuranolone New Drug Application Update

Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints

Consensus revenue estimates fall by 62%

Insider recently bought US$252k worth of stock

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)

Sage Therapeutics, Inc. to Report Q1, 2022 Results on May 03, 2022